Patents by Inventor Thomas Buser
Thomas Buser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11534406Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.Type: GrantFiled: March 18, 2020Date of Patent: December 27, 2022Assignee: Tillotts Pharma AGInventors: Felipe José Oliveira Varum, Roberto Carlos Bravo González, Thomas Buser, Abdul Waseh Basit, Ana Cristina Freire
-
Patent number: 11517534Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.Type: GrantFiled: June 2, 2017Date of Patent: December 6, 2022Assignee: Tillotts Pharma AGInventors: Felipe Josè Oliveira Varum, Roberto Carlos Bravo González, Thomas Buser, Abdul Waseh Basit, Ana Cristina Freire
-
Patent number: 11266605Abstract: The present invention relates to a modified release coated capsule and a process to obtain that capsule.Type: GrantFiled: May 13, 2015Date of Patent: March 8, 2022Assignee: TILLOTTS PHARMA AGInventors: Roberto Carlos Bravo Gonzaléz, Felipe José Oliveira Varum, Thomas Buser
-
Publication number: 20220047516Abstract: Herein described is a modified release coated capsule and a process to obtain that capsule.Type: ApplicationFiled: October 26, 2021Publication date: February 17, 2022Applicant: Tillotts Pharma AGInventors: Roberto Carlos Carlos BRAVO GONZALÉZ, Felipe José OLIVEIRA VARUM, Thomas BUSER
-
Publication number: 20220016040Abstract: A method produces a coatable core for a modified release drug formulation for oral administration. The coatable core has a high drug load of at least 70 wt % based on the total weight of the coatable core. The method involves the steps of granulating a composition containing a drug and at least one binder to form granules; blending the granules with a pharmacologically acceptable disintegrant and optionally, one or more additional pharmacologically acceptable excipients, to form a compression blend, wherein the disintegrant is present in an amount from about 0.5 wt % to about 5 wt %, based on the total weight of the coatable core; and compressing the compression blend using an external lubrication compression method to form a coatable core.Type: ApplicationFiled: December 5, 2019Publication date: January 20, 2022Applicant: Tillotts Pharma AGInventors: Thomas BUSER, Yalcin Cetinkaya-Coskun, Roberto Carlos Bravo González
-
Patent number: 11160762Abstract: The present invention relates to a modified release coated capsule and a process to obtain that capsule.Type: GrantFiled: May 13, 2015Date of Patent: November 2, 2021Assignee: Tillotts Pharma AGInventors: Roberto Carlos Bravo Gonzaléz, Felipe José Oliveira Varum, Thomas Buser
-
Patent number: 10799515Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.Type: GrantFiled: October 29, 2013Date of Patent: October 13, 2020Assignee: TILLOTTS PHARMA AGInventors: Felipe Jose Oliveira Varum, Roberto Carlos Bravo Gonzalez, Thomas Buser, Abdul Waseh Basit, Ana Cristina Freire
-
Publication number: 20200214987Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.Type: ApplicationFiled: March 18, 2020Publication date: July 9, 2020Applicant: Tillotts Pharma AGInventors: Felipe José OLIVEIRA VARUM, Roberto Carlos Bravo González, Thomas Buser, Abdul Waseh Basit, Ana Cristina Freire
-
Patent number: 10272048Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralized, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.Type: GrantFiled: September 16, 2016Date of Patent: April 30, 2019Assignee: Tillotts Pharma AGInventors: Felipe Josè Oliveira Varum, Roberto Carlos Bravo González, Thomas Buser, Abdul Waseh Basit, Ana Cristina Freire
-
Patent number: 10226430Abstract: Delayed release of a drug to the colon is achieved from a delayed release formulation comprising a core and a coating for the core. The core comprises a drug and the coating comprises an inner layer and an outer layer. The outer layer comprises a mixture of a first polymeric material which is susceptible to attack by colonic bacteria, and a second polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a third polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said third polymeric material being selected from an at least partially neutralized polycarboxylic acid and a non-ionic polymer. In embodiments in which the third polymeric material is a non-ionic polymer, the inner layer comprises at least one of a buffer agent and a base.Type: GrantFiled: April 29, 2013Date of Patent: March 12, 2019Assignee: TILLOTTS PHARMA AGInventors: Roberto Carlos Bravo Gonzalez, Thomas Buser, Frederic Jean-Claude Goutte, Abdul Waseh Basit, Felipe Jose Oliveira Varum, Ana Cristina Freire
-
Patent number: 9814681Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.Type: GrantFiled: October 29, 2013Date of Patent: November 14, 2017Assignee: Tillotts Pharma AGInventors: Felipe José Oliveira Varum, Roberto Carlos Bravo González, Thomas Buser
-
Publication number: 20170266117Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.Type: ApplicationFiled: June 2, 2017Publication date: September 21, 2017Applicant: Tillotts Phharma AGInventors: Felipe Josè OLIVEIRA VARUM, Roberto Carlos BRAVO GONZÁLEZ, Thomas BUSER, Abdul Waseh BASIT, Ana Cristina FREIRE
-
Publication number: 20170119681Abstract: The present invention relates to a modified release coated capsule and a process to obtain that capsule.Type: ApplicationFiled: May 13, 2015Publication date: May 4, 2017Applicant: TILLOTTS PHARMA AGInventors: Roberto Carlos BRAVO GONZALÉZ, Felipe José OLIVEIRA VARUM, Thomas BUSER
-
Publication number: 20170079927Abstract: The present invention relates to a modified release coated capsule and a process to obtain that capsule.Type: ApplicationFiled: May 13, 2015Publication date: March 23, 2017Applicant: Tillotts Pharma AGInventors: Roberto Carlos BRAVO GONZALÉZ, Felipe José OLIVEIRA VARUM, Thomas BUSER
-
Publication number: 20170056354Abstract: A pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form or a pharmacologically acceptable derivative thereof is contained in a soft gelatin capsule characterised in that the capsule comprises gelatin extracted by an extraction process comprising acid pre-treatment of a collagen source. One advantage of the present invention over a soft to gelatin capsule containing the same formulation but comprising gelatin extracted by an extraction process comprising alkali pre-treatment of the collagen source is that the present invention does not harden significantly over time and thus has a longer shelf life.Type: ApplicationFiled: November 14, 2016Publication date: March 2, 2017Applicant: Chrysalis Pharma AGInventors: Jean-Pierre SACHETTO, Roly BUFTON, Thomas BUSER
-
Publication number: 20170035698Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.Type: ApplicationFiled: September 16, 2016Publication date: February 9, 2017Applicant: Tillotts Pharma AGInventors: Felipe Josè OLIVEIRA VARUM, Roberto Carlos BRAVO GONZÁLEZ, Thomas BUSER, Abdul Waseh BASIT, Ana Cristina FREIRE
-
Publication number: 20160250232Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.Type: ApplicationFiled: October 29, 2013Publication date: September 1, 2016Applicant: TILLOTTS PHARMA AGInventors: Felipe Jose Oliveira VARUM, Roberto Carlos BRAVO GONZALEZ, Thomas BUSER, Abdul Waseh BASIT, Ana Cristina FREIRE
-
Patent number: 9364440Abstract: Delayed release of a drug to the colon is achieved from a delayed release formulation comprising a core and a coating for the core. The core comprises a drug and the coating comprises an outer layer and at least one layer between the core and the outer layer selected from the group consisting of an isolation layer and an inner layer. The outer layer comprises a mixture of a first polymeric material which is susceptible to attack by colonic bacteria, and a second polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a third polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said third polymeric material being selected from an at least partially neutralised polycarboxylic acid and a non-ionic polymer. In embodiments in which the third polymeric material is a non-ionic polymer, the inner layer comprises at least one of a buffer agent and a base.Type: GrantFiled: April 29, 2013Date of Patent: June 14, 2016Assignee: TILLOTTS PHARMA AGInventors: Roberto Carlos Bravo Gonzalez, Thomas Buser, Frederic Jean-Claude Goutte, Abdul Waseh Basit, Felipe Jose Oliveira Varum, Ana Cristina Freire
-
Patent number: 9132112Abstract: A pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form or a pharmacologically acceptable derivative thereof is contained in a soft gelatin capsule characterized in that the capsule comprises gelatin extracted by an extraction process comprising acid pre-treatment of a collagen source. One advantage of the present invention over a soft gelatin capsule containing the same formulation but comprising gelatin extracted by an extraction process comprising alkali pre-treatment of the collagen source is that the present invention does not harden significantly over time and thus has a longer shelf life.Type: GrantFiled: April 22, 2014Date of Patent: September 15, 2015Assignee: CHYSALIS PHARMA AGInventors: Jean-Pierre Sachetto, Roly Bufton, Thomas Buser
-
Publication number: 20150238430Abstract: A pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form or a pharmacologically acceptable derivative thereof is contained in a soft gelatin capsule characterised in that the capsule comprises gelatin extracted by an extraction process comprising acid pre-treatment of a collagen source. One advantage of the present invention over a soft gelatin capsule containing the same formulation but comprising gelatin extracted by an extraction process comprising alkali pre-treatment of the collagen source is that the present invention does not harden significantly over time and thus has a longer shelf life.Type: ApplicationFiled: April 29, 2015Publication date: August 27, 2015Applicant: Chrysalis Pharma AGInventors: Jean-Pierre SACHETTO, Roly BUFTON, Thomas BUSER